Related Experiment Video
Updated: Nov 27, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell
Xue Li1, Xin Guo1, Yuqing Zhu2
1Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China; Institute of Hematology, Zhejiang University, Hangzhou 310058, China; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou 310058, China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310058, China.
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for blood cancers. This study reveals how CAR-T cells change from proliferating to cytotoxic, offering insights into treatment effectiveness.
Area of Science:
- Immunotherapy
- Hematologic Oncology
- Single-cell Transcriptomics
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy has transformed hematological malignancy treatment.
- BCMA CAR-T cells show efficacy in relapsed/refractory multiple myeloma.
- CAR-T cell dynamics (proliferation, cytotoxicity) in patients are not well understood.
Purpose of the Study:
- To longitudinally profile T-cell transcriptomes in a plasma cell leukemia patient treated with BCMA CAR-T cells.
- To investigate the developmental trajectory and functional states of CAR-T cells during therapy.
- To identify conserved mechanisms of CAR-T cell activity across hematological malignancies.
Main Methods:
- Single-cell transcriptomic analysis of 55,488 T-cells (CAR-T products, CAR-T cells, endogenous T-cells).
- Longitudinal profiling at peak and remission phases of treatment.
- Re-analysis of a CD8+ CD19 CAR-T study for cross-validation.
Main Results:
- Distinct CAR-T and endogenous T-cell subsets identified, with stage-specific expression patterns.
- CAR-T cells transition from a proliferative to a cytotoxic state during treatment.
- Transcriptional characteristics of BCMA CAR-T and CD19 CAR-T cells are similar, particularly during the peak phase.
Conclusions:
- CAR-T cell dynamics involve a developmental trajectory from proliferation to cytotoxicity.
- Conserved mechanisms underlie CAR-T efficacy across different hematological malignancies.
- This study provides crucial insights into CAR-T cell behavior during therapy.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017